Therapeutic resistance
Beginning in the July 2009 issue, Nature Reviews Cancer will be publishing a series of articles that take a look at different aspects of therapeutic resistance. Resistance to therapy — chemotherapy or radiotherapy — is an increasing problem in the care of patients with cancer. Numerous culprits have been identified, including environmental adaptations to therapy, aberrant regulation of drug transporters and signalling feedback loops that bypass targeted therapies. As discussed in the articles in this series, multi–targeted drugs, improved understanding of feedback regulation, pathway crosstalk and resistance mechanisms, as well as predictors of response all aim to overcome this significant challenge.
2011
May 2011 Vol 11 No 5
Brain metastases as preventive and therapeutic targets
Patricia S. Steeg, Kevin A. Camphausen & Quentin R. Smith
May 2011 Vol 11 No 5
An analogy between the evolution of drug resistance in bacterial communities and malignant tissues
Guillaume Lambert, Luis Estévez-Salmeron, Steve Oh, David Liao, Beverly M. Emerson, Thea D. Tlsty & Robert H. Austin
2010
November 2010 Vol 10 No 11
Rational, biologically based treatment of EGFR–mutant non–small–cell lung cancer
William Pao & Juliann Chmielecki
March 2010 Vol 10 No 3
Microtubules and resistance to tubulin–binding agents
Maria Kavallaris
February 2010 Vol 10 No 2
Targeting the cancer kinome through polypharmacology
Zachary A. Knight, Henry Lin & Kevan M. Shokat
February 2010 Vol 10 No 2
ABC transporters in cancer: more than just drug efflux pumps
Jamie I. Fletcher, Michelle Haber, Michelle J. Henderson & Murray D. Norris
2009
September 2009 Vol 9 No 9
Biological determinants of endocrine resistance in breast cancer
Elizabeth A. Musgrove & Robert L. Sutherland
doi:10.1038/nrc2713
September 2009 Vol 9 No 9
Environment–mediated drug resistance: a major contributor to minimal residual disease
Mark B. Meads, Robert A. Gatenby & William S. Dalton
doi:10.1038/nrc2714
August 2009 Vol 9 No 8
CYP2D6 and tamoxifen: DNA matters in breast cancer
Janelle M. Hoskins, Lisa A. Carey & Howard L. McLeod
doi:10.1038/nrc2683
July 2009 Vol 9 No 7
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
José Baselga & Sandra M. Swain
doi:10.1038/nrc2656